Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Stone

Showing results (1551-1560 of 1,641) with videos related to

Pageof 165
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|January 20, 2009
JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependenceEllen E Codd, John R Carson, Raymond W Colburn, et al.
Chemmedchem|December 28, 2020
Improving Antibody-Tubulysin Conjugates through Linker Chemistry and Site-Specific ConjugationJoseph Z Hamilton, Thomas A Pires, Jamie A Mitchell, et al.
International Journal for Parasitology. Drugs and Drug Resistance|May 24, 2021
In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora caninum tachyzoites and Toxoplasma gondii oocystsDennis Imhof, Nicoleta Anghel, Pablo Winzer, et al.
Controlled Clinical Trials|June 1, 1982
National Heart, Lung, and Blood Institute type II Coronary Intervention Study: design, methods, and baseline characteristicsJ F Brensike, S F Kelsey, E R Passamani, et al.
ERJ Open Research|November 17, 2018
Association of low income with pulmonary disease progression in smokers with and without chronic obstructive pulmonary diseaseKatherine E Lowe, Barry J Make, James D Crapo, et al.
Molecular Cancer Therapeutics|January 8, 2017
Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug ConjugatesPatrick J Burke, Joseph Z Hamilton, Scott C Jeffrey, et al.
Scientific Reports|January 7, 2023
Prediction of left ventricular ejection fraction changes in heart failure patients using machine learning and electronic health records: a multi-site studyPrakash Adekkanattu, Luke V Rasmussen, Jennifer A Pacheco, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 13, 2006
The novel, orally active, delta opioid RWJ-394674 is biotransformed to the potent mu opioid RWJ-413216E E Codd, J R Carson, R W Colburn, et al.
British Journal of Haematology|July 6, 2016
Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström MacroglobulinaemiaJorge J Castillo, Ramon Garcia-Sanz, Evdoxia Hatjiharissi, et al.
Cell Reports|February 17, 2015
The Mitochondrial Metallochaperone SCO1 Is Required to Sustain Expression of the High-Affinity Copper Transporter CTR1 and Preserve Copper HomeostasisChristopher J Hlynialuk, Binbing Ling, Zakery N Baker, et al.
Pageof 165

Showing results (1551-1560 of 1,641) with videos related to

Sort By:
Pageof 165
The Journal of Pharmacology and Experimental Therapeutics|January 20, 2009
JNJ-20788560 [9-(8-azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic acid diethylamide], a selective delta opioid receptor agonist, is a potent and efficacious antihyperalgesic agent that does not produce respiratory depression, pharmacologic tolerance, or physical dependenceEllen E Codd, John R Carson, Raymond W Colburn, et al.
Chemmedchem|December 28, 2020
Improving Antibody-Tubulysin Conjugates through Linker Chemistry and Site-Specific ConjugationJoseph Z Hamilton, Thomas A Pires, Jamie A Mitchell, et al.
International Journal for Parasitology. Drugs and Drug Resistance|May 24, 2021
In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora caninum tachyzoites and Toxoplasma gondii oocystsDennis Imhof, Nicoleta Anghel, Pablo Winzer, et al.
Controlled Clinical Trials|June 1, 1982
National Heart, Lung, and Blood Institute type II Coronary Intervention Study: design, methods, and baseline characteristicsJ F Brensike, S F Kelsey, E R Passamani, et al.
ERJ Open Research|November 17, 2018
Association of low income with pulmonary disease progression in smokers with and without chronic obstructive pulmonary diseaseKatherine E Lowe, Barry J Make, James D Crapo, et al.
Molecular Cancer Therapeutics|January 8, 2017
Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug ConjugatesPatrick J Burke, Joseph Z Hamilton, Scott C Jeffrey, et al.
Scientific Reports|January 7, 2023
Prediction of left ventricular ejection fraction changes in heart failure patients using machine learning and electronic health records: a multi-site studyPrakash Adekkanattu, Luke V Rasmussen, Jennifer A Pacheco, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 13, 2006
The novel, orally active, delta opioid RWJ-394674 is biotransformed to the potent mu opioid RWJ-413216E E Codd, J R Carson, R W Colburn, et al.
British Journal of Haematology|July 6, 2016
Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström MacroglobulinaemiaJorge J Castillo, Ramon Garcia-Sanz, Evdoxia Hatjiharissi, et al.
Cell Reports|February 17, 2015
The Mitochondrial Metallochaperone SCO1 Is Required to Sustain Expression of the High-Affinity Copper Transporter CTR1 and Preserve Copper HomeostasisChristopher J Hlynialuk, Binbing Ling, Zakery N Baker, et al.
Pageof 165